Identification of DLC-1 expression and methylation status in patients with non-small-cell lung cancer

被引:11
|
作者
Feng, Hongxiang [1 ]
Zhang, Zhengrong [1 ]
Wang, Xiaowei [1 ]
Liu, Deruo [1 ]
机构
[1] China Japan Friendship Hosp, Dept Thorac Surg, 2 Yinghua East Rd, Beijing 100029, Peoples R China
关键词
expression; methylation; deleted in liver cancer-1; non-small-cell lung carcinomas;
D O I
10.3892/mco.2015.681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to determine whether the deleted in liver cancer-1 (DLC-1) gene is deregulated in non-small-cell lung carcinoma (NSCLC) and to assess the contribution of molecular alterations in DLC-1 to lung carcinogenesis, a total of 84 tissue specimens (30 NSCLC and 30 corresponding adjacent normal tissues; 5 benign tumor and 5 corresponding adjacent normal tissues; and 10 pulmonary bullae and 4 corresponding adjacent normal tissues), were obtained from 45 patients who underwent curative surgical resection. DLC-1 mRNA expression was evaluated by reverse transcription-quantitative polymerase chain reaction (PCR) and its protein level was assessed by western blot analysis. A significant downregulation of DCL-1 at the mRNA and protein levels was observed in NSCLC tissues when compared to benign lung tumors and normal lung tissues (P<0.001). To further determine whether the decreased expression of DLC-1 at the mRNA and protein levels is associated with the methylation of its promoter, methylation-specific PCR was performed following extraction of genomic DNA from the samples. DLC-1 promoter methylation was identified in 7 of the 30 (23.3%) NSCLC tissue samples, but not in the corresponding adjacent normal tissues from NSCLC patients or in lung tissues from non-NSCLC patients. Our data indicated that DLC-1 hypermethylation may play a crucial role in lung carcinogenesis and may be a target for the treatment of NSCLC.
引用
收藏
页码:249 / 254
页数:6
相关论文
共 50 条
  • [41] Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer
    Limacher, Jean-Marc
    Spring-Giusti, Clementine
    Bellon, Nadine
    Ancian, Philippe
    Rooke, Ronald
    Bonnefoy, Jean-Yves
    EXPERT REVIEW OF VACCINES, 2013, 12 (03) : 263 - 270
  • [42] A panel of noncoding RNAs in non-small-cell lung cancer
    Bagheri, Abouzar
    Khorshid, Hamid Reza Khorram
    Tavallaie, Mahmood
    Mowla, Seyed Javad
    Sherafatian, Masih
    Rashidi, Mohsen
    Zargari, Mehryar
    Boroujeni, Mahdi Eskandarian
    Hosseini, Sayed Mostafa
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (05) : 8280 - 8290
  • [43] Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations
    Liu, Fangfang
    Yuan, Xun
    Jiang, Jizong
    Chu, Qian
    IMMUNOTHERAPY, 2020, 12 (16) : 1195 - 1207
  • [44] Effect of Smac and Taxol on non-small-cell lung cancer
    Peng, Chuanliang
    Hao, Yingtao
    Zhao, Yunpeng
    Sun, Qifeng
    Zhao, Xiaogang
    Cong, Bo
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2014, 46 (05) : 387 - 393
  • [45] Cetuximab and non-small-cell lung cancer: end of the story?
    Rossi, Antonio
    LANCET ONCOLOGY, 2013, 14 (13) : 1251 - 1253
  • [46] The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients
    Kuang, Bo-hua
    Wen, Xi-zhi
    Ding, Ya
    Peng, Rui-qing
    Cai, Pei-qiang
    Zhang, Meng-qing
    Jiang, Feng
    Zhang, Xiao-shi
    Zhang, Xing
    MEDICAL ONCOLOGY, 2013, 30 (02)
  • [47] Aberrant methylation in non-small cell lung cancer
    Makoto Suzuki
    Ichiro Yoshino
    Surgery Today, 2010, 40 : 602 - 607
  • [48] Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
    Sunaga, Noriaki
    Miura, Yosuke
    Kasahara, Norimitsu
    Sakurai, Reiko
    CANCERS, 2021, 13 (23)
  • [49] Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer
    Schiwitza, Annett
    Schildhaus, Hans-Ulrich
    Zwerger, Birgit
    Rueschoff, Josef
    Reinhardt, Christian
    Leha, Andreas
    Andreas, Stefan
    Rittmeyer, Achim
    IMMUNOTHERAPY, 2019, 11 (09) : 769 - 782
  • [50] Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
    Hiley, Crispin T.
    Le Quesne, John
    Santis, George
    Sharpe, Rowena
    de Castro, David Gonzalez
    Middleton, Gary
    Swanton, Charles
    LANCET, 2016, 388 (10048) : 1002 - 1011